Salarius Pharmaceuticals Inc (NASDAQ: SLRX) Embarks On A New Trial To Study Seclidemstat

Salarius Pharmaceuticals Inc (NASDAQ: SLRX) embark on a clinical trial that seeks to investigate a novel lysine-specific demethylase 1 (LSD1) inhibitor called seclidemstat. This biopharmaceutical company has, over the years, focused n the development of working medicines to help out persons struggling with solid tumors,  pediatric cancers, and other cancers.

Conducting the studies

According to a company report, the University of Texas’ Dr. Guillermo Montalban-Bravo will be the one leading the exercise. The official works in the Department of Leukemia in the university, and the trial is expected to be an open-label one.

The trial seeks to find some quality doses and will also be seeking to attain major expansions in that regard. It will be about determining the maximum tolerated dose (MTD), which is in close consideration to an instance where the substance is used together with azacytidine.  The study’s target is to determine the substance’s effectiveness in treating Chronic Myelomonocytic Leukemia (CMML) and Myelodysplastic Syndromes (MDS).

Both the CMML and the MDS happen to be blood cancers that could get rather severe, eventually becoming a life-threatening form of leukemia called Acute Myeloid Leukemia (AML).

Seclidemstat and azacytidine combination

The origins of the study could be closely linked to some compelling preclinical data obtained sometime back. The study was based on a combination of seclidemstat and azacytidine, in which the substance showed an anti-proliferative activity across hematologic synergy and cancers.

The Senior Vice President of Clinical Development at Salarius Pharmaceuticals, Nadeem Mirza, states, “We look forward to exploring the potential of seclidemstat in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. These are hard to treat blood cancers, and if patients progress to Acute Myeloid Leukemia, they face a bleak prognosis.”

Leave a Comment

Your email address will not be published.